Needham Maintains Buy on Veradermics, Raises Price Target to $164

Veradermics, Incorporated

Veradermics, Incorporated

MANE

0.00

Needham analyst Serge Belanger maintains Veradermics (NYSE: MANE) with a Buy and raises the price target from $136 to $164.